Celgene, Sutro Biopharma Agree on Potential $500 Million Deal

Biotech company Sutro Biopharma announced in a press release that it will be collaborating with Celgene (NASDAQ: CELG  ) on a deal  to develop antibody drug conjugates (ADCs) and bispecific antibodies for undisclosed targets. The agreement, which could be worth up to $500 million if the program succeeds, will also have the two companies working on manufacturing a proprietary antibody for Celgene.

Sutro will pick up an upfront payment of a "substantial" sum, according to the release, as well as equity investment in the company and payouts for hitting program milestones. Sutro could also receive royalties on any drug sales from Celgene if the program is a success.

Sutro CEO William Newell added his take on the agreement, saying in the release:

The scope of this partnership showcases our novel, cell-free approach to designing, developing and manufacturing next-generation ADCs and bispecific antibodies.

Sutro will handle product design and will produce pre-clinical material as part of the program. Celgene and Sutro's deal comes after several other companies  have looked into producing ADCs, including a partnership between Abbot Labs (NYSE: ABT  ) and Seattle Genetics. Menarini and Oxford BioTherapeutics recently also signed a deal to develop ADCs that could be worth more than $1 billion.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2164983, ~/Articles/ArticleHandler.aspx, 4/18/2014 4:41:02 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

TREND TRACKER: Get Rich When the Web Goes Dark

It's time to say "goodbye" to your Internet! One bleeding-edge technology is about to put the World Wide Web to bed. And if you act right away, it could make you wildly rich. Experts are calling it the single largest business opportunity in the history of capitalism… The Economist is calling it "transformative"... but you'll probably just call it "how I made my millions." Big money is already on the move. Don't be too late to the party – find out the 1 stock to own when the Web goes dark.